NCT02890069 2023-01-11
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase 1 Completed
Novartis
University of California, Davis
University of Pittsburgh
Medical University of South Carolina
University of Pittsburgh
Cancer Trials Ireland
Southern Europe New Drug Organization